Iovance Biotherapeutics Posts 30% Quarterly Revenue Growth, Eyes 2027 Lifileucel Launch
Event summary
- Iovance reported $87M in Q4 2025 revenue, up 30% QoQ, driven by Amtagvi demand.
- Full-year 2025 revenue hit $264M, meeting guidance, with Amtagvi contributing $220M.
- FDA granted Fast Track designation for lifileucel in second-line advanced NSCLC.
- Cash position of $303M as of December 31, 2025, expected to fund operations into Q3 2027.
- Amtagvi achieved 44% overall objective response rate in real-world data.
The big picture
Iovance's strong Q4 2025 results underscore the growing demand for Amtagvi in the U.S., while the FDA's Fast Track designation for lifileucel positions the company to expand its TIL therapy portfolio. The biotech's focus on operational excellence and global regulatory approvals reflects broader industry trends toward scalable cell therapies and earlier treatment interventions in oncology. With a cash runway extending into 2027, Iovance is poised to capitalize on its leadership in TIL therapies, though execution risks remain in manufacturing and clinical development.
What we're watching
- Commercial Momentum
- Whether Amtagvi's real-world response rates can sustain adoption trends and drive further revenue growth in 2026.
- Regulatory Milestones
- The pace at which lifileucel advances through its registrational trial and secures potential 2H27 launch approval.
- Operational Efficiency
- How internalization of lifileucel manufacturing and R&D optimization impact gross margins and operating expenses in 2026-2027.
Related topics